Author(s)

Toshiyuki Ochiya

Affiliation(s)

Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama 7008558, Japan.

Corresponding Author

Toshiyuki Ochiya

ABSTRACT

Soft tissue sarcoma is a highly heterogeneous malignant tumor derived from mesenchymal tissue. Due to its large number of histological subtypes and clinical and histopathological uncertainties, current diagnosis and treatment are very difficult. One of the important clinical issues is the lack of useful biomarkers; therefore, the discovery of biomarkers that can be used to detect tumor response to chemotherapy or radiotherapy may help clinicians provide more effective clinical management. Studying microRNA in soft tissue sarcomas provides clues to solving the problem. The discovery of evidence such as differential microRNA in soft tissue sarcoma and circulating microRNA in patient serum has the potential to accelerate the transition to clinical application, which undoubtedly brings new hope for the eradication of soft tissue sarcoma. 

KEYWORDS

MicroRNA; Soft tissue sarcoma; Biomarkers; Treatment

CITE THIS PAPER

Toshiyuki Ochiya. Abnormal expression of microrna and biomarkers in soft tissue sarcoma. World Journal of Biomedical Sciences. 2024, 2(2): 10-13. DOI: 10.61784/wjbsv2n231.

REFERENCES

[1] Subramanian S, Lui WO, Lee CH. Micro RNA expression signature of human sarcomas. Oncogene, 2008, 27(14): 2015-2026.

[2] Guled M, Pazzaglia L, Borze I. Differentiating soft tissue leiomyosarcoma and undifferentiated pleomorphic sarcoma: a miRNA analysis. Genes Chromosomes Cancer, 2014, 53(8): 693-702.

[3] Renner M, Czwan E, Hartmann W. MicroRNA profiling of primary high-grade soft tissue sarcomas. Genes Chromosomes Cancer, 2012, 51(11): 982-996.

[4] Garofalo M, Jeon YJ, Nuovo GJ. Correction: MiR-34a/c-Dependent PDGFR-ery downregulation inhibits tumorigenesis and enhances TRAIL-induced apoptosis in lung cancer. Plos One, 2015, 10(6): 113-124.

[5] Fletcher CDM. The evolving classification of soft tissue tumours -an update based on the nwe 2013 WHO classification. Pathology, 2006, 64(1): 2-11.

[6] Ugras S, Brill E, Jacobsen A. Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma. Cancer Res, 2011, 71(17): 5659-5669.

[7] Taylor BS, Decarolis PL, Angeles CV. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discov, 2011, 1(7): 587-597.

[8] Hisaoka M, Matsuyama A, Nakamoto M. Aberrant calreticulin expressionis involved in the dedifferentiation of dedifferentiated liposarcoma. Am J Pathol, 2012, 180(5): 2076-2083.

[9] Lee DH, Amanat S, Goff C. Abstract 4203: overexpression of miR-26a-2 in human liposarcoma is correlated with poor patient survival. Oncogenesis, 2013, 2(5): 47.

[10] Gie?la M, Dulak J, Józkowicz A. MicroRNAs and epigenetic mechanisms of rhabdomyosarcoma, development. Int J Biochem Cell Biol, 2014, 53(8): 482-492.

[11] NovákJ, VinklárekJ, Ondex J. MicroRNAs involved in skeletal muscle development and their roles in rhabdomyosarcoma pathogenesis. Pediatr Blood Cancer, 2013, 60(11): 1739-1746.

[12] Missiaglia E, Shepherd CJ, Patel S. MicroRNA-206 expres sion levels correlate with clinical behaviour of rhabdomyosarcomas. Br J Cancer, 2010, 102(12): 1769-1777.

[13] Rota R, Ciarapica R, Giordano A. MicroRNAs in rhabdomyo?sarcoma: pathogenetic implications and translational potentiality. Molecular Cancer, 2011, 10(27): 2140-2145.

[14] Chen CF, He XL, Arslan AD. Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIα and drug responsiveness. Molecular Pharmacol, 2011, 79(4): 735-741.

[15] Wakamatsu T, Naka N, Sasagawa S. Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascularendothelial growth factor-and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma. Cancer Sci, 2014, 105(9): 1124-1134.

[16] Kubo T, Shimose S, Fujimori J. Prognostic value of SS18-ssx of SS184-targeted therapy in synovial sarcoma: systematic review and meta-analysis. Springerplus, 2015, 4(1): 1-7.

[17] Tamaki S, Fukuta M, Sekiguchi K. SS18-SSX, the oncogenic fusion protein in synovial sarcoma, is a cellular context-dependent epigenetic modifier. Plos One, 2015, 10(11): e0142991.

[18] Minami Y, Kohsaka S, Tsuda M. SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1. Cancer Sci, 2014, 105(9): 1152-1159.

[19] Subramanian S, Thayanithy V, West RB. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. Experientia, 2010, 220(1): 58-70.

[20] Itani S, Kunisada T, Morimoto Y. MicroRNA-21 correlates with tumorigenesis in malignant peripheral nerve sheath tumor (MPNST)via programmed cell death protein 4(PDCD4). J Cancer Res Clin Oncol, 2012, 138(9): 1501-1509.

[21] Presneau N, Eskandarpour M, Shemais T. MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as atumour suppressor gene involved in tumour progression. Br J Cancer, 2013, 108(4): 964-972.

[22] Zhang P, Garnett J, Creighton CJ. EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. J Pathol, 2014, 232(3): 308-318.

[23] Italiano A, Thomas R, Breen M. The miR cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. Genes Chromosomes Cancer, 2012, 51(6): 569-578.

[24] Liu P, Wilson MJ. miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/ MEK/Erk signaling pathway and NF-kB factor. J Cellular Physiol, 2012, 227(2): 867-876.

[25] Weng C, Dong H, Chen G. miR-409-3p inhibits HT1080 cell proliferation , vascularization and metastasis by targeting angiogenin. Cancer Lett, 2012, 323(2): 171-179.

[26] Papp G, Krausz T, Stricker TP. SMARCB1, expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on both mRNA and protein levels. Genes Chromosomes Cancer, 2014, 53(2): 168-176.

[27] Cantara S, Pilli T, Sebastiani G. Circulating miRNA95 and miRNA190 are sensitive markers for the differential diagnosis of thyroid nodules in a Caucasian population. J Clin Endocrinol Metabolism, 2014, 99(11): 4190-4198.

[28] Duroux-Richard I, Pers YM, Fabre S. Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis. Mediators Inflammation, 2014, 2014(23): 342524.

[29] El-Abd NE, Fawzy NA, El-Sheikh SM. Circulating miRNA- 122, miRNA-199a, and miRNA-16 as biomarkers for early detec tion of hepatocellular carcinoma in egyptian patients with chronic hepatitis C virus infection. Molecular Diagnosis Ther, 2015, 19 (4): 213-220.

[30] Fujiwara T. Circulating MicroRNAs in sarcoma: potential biomarkers for diagnosis and targets for therapy. 2014, 3(123): 2.

[31] Miyachi M, Tsuchiya KH, Yagyu S. Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochem Biophysical Res Comm, 2010, 400 (1): 89-93.

[32] Weng Y, Chen Y, Chen J. Identification of serum microRNAs in genome-wide serum microRNA expression profiles as novel noninvasive biomarkers for malignant peripheral nerve sheath tumor diagnosis. Med Oncol, 2013, 30(2):1-6.